Cambridge, MA, April 18— Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to announce  Pharma.AI Day 2025, the brand-new quarterly update series for Pharma.AI, scheduled on April 24, 10:00-11:00 AM EST. Register here to join Alex Zhavoronkov PhD, Founder and CEO of Insilico Medicine, and get a deep dive into a series of AI breakthroughs and new product demos.

An Osaka Metropolitan University-led research team conducted a meta-analysis of the diagnostic capabilities of generative AI in the field of medicine using 83 research papers.

Researchers led by Jean-Paul Noel at the University of Minnesota, United States, have decoupled intentions, actions and their effects by manipulating the brain-machine interface that allows a person with otherwise paralyzed arms and legs to squeeze a ball when they want to. Published in the open-access journal PLOS Biology on April 17^th, the study reveals temporal binding between intentions and actions, which makes actions seem to happen faster when they are intentional.

Shawn Demehri, MD, PhD, a physician-investigator in the Cutaneous Biology Research Center and Krantz Family Center for Cancer Research at Massachusetts General Hospital and an Associate Professor of Dermatology at Harvard Medical School in the senior author of a new study in Cell Reports, Epigenomic Regulation of Stemness Contributes to the Low Immunogenicity of the Most Mutated Human Cancer.